Keyturda+化疗改善了抗白金抗卵巢癌的存活率,其累进或死亡风险降低30%。 Keytruda plus chemo improved survival in platinum-resistant ovarian cancer, with a 30% lower risk of progression or death.

Merck在2025年ESMO大会上介绍了第3阶段KEYNOTE-B96试验结果,表明将Keyturda加入化疗极大地改善了抗白金抗性复发卵巢癌患者的无进展存活率,与仅化疗相比,将疾病增发或死亡的风险降低了30%。 Merck presented Phase 3 KEYNOTE-B96 trial results at ESMO Congress 2025, showing that adding Keytruda to chemotherapy significantly improved progression-free survival in patients with platinum-resistant recurrent ovarian cancer, reducing the risk of disease progression or death by 30% compared to chemotherapy alone. 这些数据以15.6个月的中位跟踪为基础,标志着该患者群体首次从抗PD-1治疗获得生存的临床证据。 The data, based on a median follow-up of 15.6 months, marked the first clinical evidence of a survival benefit from an anti-PD-1 therapy in this patient group. 在一项单独分析中,Keytruda和Lenvima组合证明,在晚期子宫颈癌的化疗方面,特别是在没有新的安全关切的情况下,对有不匹配的修复能力强的肿瘤的病人而言,可持久地提供为期五年的生存福利。 In a separate analysis, the Keytruda and Lenvima combination demonstrated durable five-year survival benefits over chemotherapy in advanced endometrial cancer, particularly in patients with mismatch repair proficient tumors, with no new safety concerns.